What is the recommended treatment for non‑alcoholic fatty liver disease (NAFLD)?

How to Treat Fatty Liver Disease

Lifestyle modification with weight loss of 5-10% is the cornerstone of treatment for all NAFLD patients, combined with aerobic exercise 3-5 times weekly and Mediterranean diet, while pharmacotherapy should be reserved only for biopsy-proven NASH with significant fibrosis. 1, 2

Initial Management for All NAFLD Patients

All patients with NAFLD require lifestyle interventions regardless of disease severity 1, 3:

Weight Loss Targets

• Minimum 5-7% weight loss improves steatosis and inflammation 3
• 10% weight loss improves fibrosis in 45% of patients 3
• Rate matters: Gradual weight loss (<1 kg/week) is essential—rapid weight loss can worsen portal inflammation and fibrosis 3
• Even non-obese NAFLD patients benefit from 3-5% weight loss 3

Dietary Approach

The Mediterranean diet has the strongest evidence 4, 2, 5:

• Low in saturated fat and refined carbohydrates
• High in monounsaturated fats (olive oil), vegetables, fruits, whole grains, legumes
• Moderate fish and white meat consumption
• Minimal red meat and processed foods
• Avoid fructose-enriched beverages and processed foods 5

Caloric targets 3:

• Men: 1,500-1,800 kcal/day
• Women: 1,200-1,500 kcal/day
• This achieves >500 kcal/day reduction

Exercise Requirements

1, 2, 5

• Aerobic exercise: 30-60 minutes, 3-5 days/week at moderate intensity
• Resistance training: 20-30 minutes, 2-3 times/week
• Target: 150-200 minutes/week total moderate-intensity activity
• Exercise reduces liver fat even without significant weight loss 5

Alcohol Limits

• Women: ≤1 drink/day
• Men: ≤2 drinks/day
• Total abstinence mandatory in NASH cirrhosis 5

Comorbidity Management

Cardiovascular Risk Assessment 1

Evaluate and aggressively treat:

• Dyslipidemia: Statins are safe and effective in NAFLD—use them 1
• Hypertension
• Diabetes (see below)
• Obtain: lipid profile, fasting glucose/HbA1c, waist circumference, BMI

Diabetes Management 2

Preferred agents that improve NAFLD:

1. GLP-1 receptor agonists (especially semaglutide—strongest evidence for steatohepatitis resolution) 2
2. Pioglitazone (improves steatohepatitis and fibrosis) 2
3. SGLT2 inhibitors (for cardiovascular/renal protection, though limited liver histology benefit) 2

Avoid or use cautiously: Sulfonylureas and insulin increase HCC risk 3

Metformin: Safe but does NOT improve liver histology—continue only if needed for diabetes 1, 5

Medication Review 1

Discontinue drugs that worsen steatosis:

• Corticosteroids
• Amiodarone
• Methotrexate
• Tamoxifen
• Estrogens
• Tetracyclines
• Valproic acid

Who Needs Pharmacotherapy?

Pharmacotherapy is indicated ONLY for 1, 3:

• Biopsy-proven NASH with significant fibrosis (≥F2)
• OR patients at high risk: diabetes/metabolic syndrome with elevated liver enzymes

Do NOT treat simple steatosis without inflammation pharmacologically 5

Pharmacotherapy Options for NASH

For Non-Diabetic NASH Patients 1, 5

Vitamin E 800 IU/day:

• Improves steatohepatitis in non-diabetic patients
• Consider in biopsy-proven NASH without cirrhosis
• Use cautiously—monitor for adverse effects

For Diabetic NASH Patients 2, 5

Pioglitazone:

• Improves all histological features except fibrosis
• Effective in diabetic NASH patients
• Monitor for weight gain, bone fractures, heart failure

GLP-1 receptor agonists (particularly semaglutide):

• Best evidence for NASH resolution
• Additional cardiovascular benefits
• Promotes weight loss

Combination Approach 4

European guidelines suggest: Pioglitazone or Vitamin E + high-dose UDCA for 1-2 years in selected NASH patients 4

Advanced Interventions for Obesity

Structured Weight Loss Programs 2, 6

• More effective than office-based counseling alone
• Should be utilized before considering medications or surgery
• Include both dietary and exercise components

Anti-Obesity Medications 2

Consider when lifestyle modifications fail:

• Phentermine/topiramate ER
• Naltrexone/bupropion
• Liraglutide 3 mg/day
• Semaglutide 2.4 mg/week
• Orlistat

Bariatric Surgery 2, 7, 6

Strong consideration for:

• Obesity with NASH and significant fibrosis
• Patients meeting national bariatric surgery criteria
• Results: 85% NASH resolution, 88% steatosis improvement, 59% steatohepatitis improvement 7
• Safe even in compensated cirrhosis 7
• Avoid in decompensated cirrhosis 2

Monitoring and Surveillance

Baseline Evaluation 1

• Liver ultrasound
• CBC, comprehensive metabolic panel
• Liver enzymes (AST, ALT, bilirubin, alkaline phosphatase)
• INR, creatinine

Consider Liver Biopsy If 1:

• Diabetes and/or metabolic syndrome (high risk for NASH/fibrosis)
• Findings suggesting cirrhosis: thrombocytopenia, AST>ALT, hypoalbuminemia
• Undergoing cholecystectomy or bariatric surgery (low-risk intraoperative biopsy)

Cirrhosis Surveillance 1, 2

If cirrhosis confirmed:

• HCC screening: Ultrasound every 6 months
• Varices screening: EGD if LSM >20 kPa or platelets <150,000/mm²
• Transplant referral when appropriate

Key Pitfalls to Avoid

1. Don't prescribe metformin specifically for NAFLD—it doesn't improve liver histology 1, 5
2. Don't recommend rapid weight loss—can worsen inflammation and fibrosis 3
3. Don't use pharmacotherapy for simple steatosis—reserve for biopsy-proven NASH 5
4. Don't avoid statins—they are safe and reduce HCC risk 1, 3
5. Don't forget cardiovascular risk—it's the leading cause of death in NAFLD, not liver disease 3

Risk Stratification for Treatment Intensity

Low risk (simple steatosis, no/minimal fibrosis):

• Lifestyle modification only
• Treat metabolic comorbidities
• No liver-specific pharmacotherapy 5

High risk (NASH with ≥F2 fibrosis, diabetes, metabolic syndrome):

• Aggressive lifestyle modification
• Consider structured weight loss programs
• Pharmacotherapy (Vitamin E, pioglitazone, or GLP-1 RA)
• Consider bariatric surgery if obese
• Hepatology referral 1, 2, 6

Cirrhosis:

• All of the above
• HCC and varices surveillance
• Transplant evaluation if decompensated 1, 2